Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents-论文-万方医学网

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

导出原文传递

翻译打印收藏纠错

作者： Shah, Harsh ^[1] ; Jang, Hyejeong ^[2] ; Singh, Paramveer ^[3] ; Kosti, Jorgena ; Kin, Andrew ; Alavi, Asif ; Ratanatharathorn, Voravit ; Ayash, Lois ; Uberti, Joseph ; Ramchandren, Radhakrishnan ; Kim, Seongho ; Deol, Abhinav

作者单位： Huntsman Canc Ctr,Univ Utah ^[1] Karmanos Canc Inst,Wayne State Univ ^[2] Div Hematol Oncol,Univ Tennessee ^[3]

关键词 Autologous stem cell transplant Hodgkin's lymphoma novel agents POSITRON-EMISSION-TOMOGRAPHY STEM-CELL TRANSPLANTATION RESPONSE CRITERIA INTERNATIONAL WORKSHOP BRENTUXIMAB VEDOTIN ADAPTED TREATMENT CHEMOTHERAPY THERAPY RADIOTHERAPY NIVOLUMAB

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

相似文献

相关期刊

检索历史清除